A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland (Q40896877)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland |
scientific article |
Statements
1 reference
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland (English)
1 reference
Schmid HP
1 reference
Maibach R
1 reference
Bernhard J
1 reference
Hering F
1 reference
Hanselmann S
1 reference
Gusset H
1 reference
Morant R
1 reference
Pestalozzi D
1 reference
Castiglione M
1 reference
1 May 1997
1 reference
Identifiers
1 reference